ProfileGDS5678 / 1424427_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 85% 84% 84% 83% 84% 85% 84% 85% 84% 86% 86% 84% 85% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.3228785
GSM967853U87-EV human glioblastoma xenograft - Control 26.309484
GSM967854U87-EV human glioblastoma xenograft - Control 36.1811984
GSM967855U87-EV human glioblastoma xenograft - Control 46.2490683
GSM967856U87-EV human glioblastoma xenograft - Control 56.2464584
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.1390985
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.0804284
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.2787885
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.2656884
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.6215686
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.528286
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.2751284
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.293585
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.3905385